NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Peter R Carroll, J Kellogg Parsons, Gerald Andriole, Robert R Bahnson, Erik P Castle, William J Catalona, Douglas M Dahl, John W Davis, Jonathan I Epstein, Ruth B Etzioni, Thomas Farrington, George P Hemstreet 3rd, Mark H Kawachi, Simon Kim, Paul H Lange, Kevin R Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M Morgan, Kelvin A Moses, Robert B Nadler, Michael Poch, Chuck Scales, Terrence M Shaneyfelt, Marc C Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J Vickers, Robert Wake, Dorothy A Shead, Deborah A Freedman-Cass, Peter R Carroll, J Kellogg Parsons, Gerald Andriole, Robert R Bahnson, Erik P Castle, William J Catalona, Douglas M Dahl, John W Davis, Jonathan I Epstein, Ruth B Etzioni, Thomas Farrington, George P Hemstreet 3rd, Mark H Kawachi, Simon Kim, Paul H Lange, Kevin R Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M Morgan, Kelvin A Moses, Robert B Nadler, Michael Poch, Chuck Scales, Terrence M Shaneyfelt, Marc C Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J Vickers, Robert Wake, Dorothy A Shead, Deborah A Freedman-Cass
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.
Copyright © 2016 by the National Comprehensive Cancer Network.
Source: PubMed